StockData
Tyra Biosciences, Inc. logo

Tyra Biosciences, Inc. (TYRA) stock

TYRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$19.61+0.04 (+0.20%)

Close on Nov 18, 2026Market cap $1.17BP/E –Yield –

Tyra Biosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Tyra Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$160.46M. For fiscal 2025 it was -$132.76M. The highest annual figure on record is -$9.30M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$132.76M–
FY2024Dec 31, 2024-$104.18M–
FY2023Dec 31, 2023-$79.95M–
FY2022Dec 31, 2022-$58.93M–
FY2021Dec 31, 2021-$26.29M–
FY2020Dec 31, 2020-$9.30M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$49.00M–
Q1 FY2026Mar 31, 2026-$42.00M–
Q4 FY2025Dec 31, 2025-$36.52M–
Q3 FY2025Sep 30, 2025-$32.94M–
Q2 FY2025Jun 30, 2025-$31.45M–
Q1 FY2025Mar 31, 2025-$31.85M–
Q4 FY2024Dec 31, 2024-$29.74M–
Q3 FY2024Sep 30, 2024-$28.60M–
Q2 FY2024Jun 30, 2024-$23.53M–
Q1 FY2024Mar 31, 2024-$22.32M–
Q4 FY2023Dec 31, 2023-$25.63M–
Q3 FY2023Sep 30, 2023-$23.96M–
Q2 FY2023Jun 30, 2023-$16.01M–
Q1 FY2023Mar 31, 2023-$14.33M–
Q4 FY2022Dec 31, 2022-$15.02M–
Q3 FY2022Sep 30, 2022-$13.65M–
Q2 FY2022Jun 30, 2022-$15.43M–
Q1 FY2022Mar 31, 2022-$14.83M–
Q4 FY2021Dec 31, 2021-$9.93M–
Q3 FY2021Sep 30, 2021-$6.64M–
Q2 FY2021Jun 30, 2021-$5.51M–
Q1 FY2021Mar 31, 2021-$4.21M–
Q4 FY2020Dec 31, 2020-$3.68M–
Q3 FY2020Sep 30, 2020-$2.33M–

More Tyra Biosciences figures

See a number that looks wrong?